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Abstract
Background: Serum C-reactive protein (CRP), an acute inflammatory response biomarker, has been recognized as
an indicator of malignant disease progression. However, the prognostic significance of CRP levels collected before
tumor removal in intrahepatic cholangiocarcinoma requires further investigation.
Methods: We sampled the CRP levels in 140 patients with intrahepatic cholangiocarcinoma who underwent
hepatectomies with regional lymphadenectomies between 2006 and 2013. A retrospective analysis of the
clinicopathological data was performed. We focused on the impact of serum CRP on the patients’ cancer-specific
survival and recurrence-free survival rates.
Results: High levels of preoperative serum CRP were significantly associated with well-established clinicopathologic
features, including gender, advanced tumor stage, and elevated carcinoembryonic antigen and carbohydrate
antigen 19-9 levels (P < 0.05). Univariate analysis demonstrated a significant association between high levels of
serum CRP and adverse cancer-specific survival (P = 0.001) and recurrence-free survival (P < 0.001). In patients with
stage I/II intrahepatic cholangiocarcinoma, the serum CRP level was a prognostic indicator for cancer-specific
survival. In patients with stage I/II or stage III/IV, the serum CRP level was a prognostic indicator for recurrence-free
survival (P < 0.05). Additionally, multivariate analysis identified serum CRP level in intrahepatic cholangiocarcinoma
as an independent prognostic factor (P < 0.05).
Conclusions: We confirmed a significant association of elevated pre-operative CRP levels with poor clinical
outcomes for the tested patients with intrahepatic cholangiocarcinoma. Our results indicate that the serum CRP
level may represent a useful factor for patient stratification in intrahepatic cholangiocarcinoma management.
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Background
Cholangiocarcinoma is a relatively rare neoplasm acquired
by humans. Recently, high incidence rates have been
reported in Eastern Asia, and especially in Thailand [1].
Based on the location in the body where it develops,
cholangiocarcinoma is further classified into intrahepatic,
perihilar extrahepatic, or distal extrahepatic. Intrahepatic
cholangiocarcinoma (IHCC) originates from the second
segment of the bile duct, and is the least common of the
cholangiocarcinoma classifications that a person could ac-
quire. It accounts for 8–10 % of total cholangiocarcinoma
cases diagnosed [2]. Its etiology is unknown, although vari-
ous risk factors, including primary sclerosing cholangitis
[3], liver fluke infestation [4], hepatolithiasis [5], and hepa-
titis viruses [6, 7], have been identified. These risk factors
all induce a chronic inflammation in the biliary epithelium
and partially obstruct the bile duct [8]. These risk factors
are considered to be favorable for potential cancer devel-
opment [8]. IHCC is seemingly incurable, has a rapid
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progression, and is lethal in most cases, with the 5-years
survival rate being less than 5 % for non-resectable cases
[9]. Surgical resection offers only a chance to cure IHCC,
but the outcomes vary widely across affected patients.
Several prognostic factors have been identified for the
prediction of IHCC patient survival. These factors in-
clude staging [10], para-aortic lymph node status [11],
positive node to the total node ratio [12], tumor size,
and the presence of multiple tumors [13]. Other novel
molecular biomarkers, such as hepatoma-derived growth
factor [14], SOX4 [15], loss of FBXW7 expression [16],
Homer1 [17], and inactivation of Smad4 [18], seem to be
associated with poor IHCC patient prognosis. Despite
these critical association findings, the majority of these
histological predictors only apply to assessments con-
ducted after surgical intervention. Consequently, there is
an urgent need to identify pre-treatment prognostic
markers that can be used for an improved risk stratified
treatment approach for patients that have not undergone
surgical intervention.
Serum C-reactive protein (CRP), an acute phase reactive
protein, has been defined as an inflammatory biomarker
produced in response to pro-inflammatory cytokine
hepatocyte stimulation [19]. As a result, CRP is closely as-
sociated with the development and outcome of many dis-
eases [19]. During the past decade, elevated serum CRP
has been associated with poorer prognosis in patients with
various malignant cancers, including gastric cancer, colo-
rectal cancer, breast cancer, and urological cancer [20–25].
This linkage implies a close association between inflam-
mation and malignancy. A recent study has also revealed
that chronic inflammation and pro-inflammatory cyto-
kines, like interleukin 6 (IL-6), play an important role in
the development and progression of cholangiocarcinoma
[26]. Based on these conclusions, it seems as though CRP
may be a promising prognostic factor that could be incor-
porated into prognostic models to improve the predictive
accuracy of the outcomes for IHCC patients. Already, a
retrospective study has shown that the serum CRP was a
prognostic factor in a patient with a small size perihilar
cholangiocarcinoma [27]. In published literature, the rela-
tion between serum CRP and prognosis of IHCC has not
been explored yet. In this study, we aimed to explore the
prognostic significance of pre-treatment serum CRP levels
on cancer-specific survival (CSS) and recurrence-free
survival (RFS) in IHCC patients.
Methods
Patients
This retrospective study included 140 IHCC patients that
were treated at Sun Yat-sen University Cancer Center
between the years of 2006 and 2013. The patient cases
were selected for inclusion in this study based on the fol-
lowing criteria: pathological diagnosis of IHCC, primary
and curative tumor resection surgery without preoperative
anticancer treatment, the availability of preoperative
serum CRP levels, liver function and clinicopathological
and follow-up data. The IHCC cohort included 93 (66 %)
men and 47 (34 %) women with a mean age of 54.11 years.
The average follow-up time after surgery was 20.9 months
(median: 14.7 months; range: 0.55 to 87.9 months).
Follow-up evaluations were performed every 3 months
within the first year, every 6 months for the next 2 years,
and annually 3 years after the surgery. The histopatho-
logical findings of this IHCC cohort were also reviewed,
including tumor multiplicity, intraepithelial ductal spread
and vascular invasion. Tumor differentiation was deter-
mined based on the criteria proposed in the WHO Classi-
fication of Tumours of the Digestive System (2010
version). At the T stage, the lymph node status and the
tumor stage were defined according to the UICC/AJCC
tumor-node-metastasis (TNM) Classification System
(2010 version). Ultrasonography, computed tomography
(CT), or magnetic resonance imaging (MRI) scanning
were used to detect tumor recurrence, which included in-
cidences of intrahepatic recurrence or metastasis. The
time of detection was used as the time of recurrence. In
our study, the RFS was defined as the time from surgery
to IHCC recurrence or patient death from IHCC, which-
ever came first in each individual case. The CSS was the
time from the date of surgery to the last follow-up visit or
date of death from IHCC. The Institute Research Medical
Ethics Committee of Sun Yat-sen University Cancer
Center approved the methods used in this study.
Detection of serum CRP
Serum CRP levels were detected by the biosensor. To be
included in the study, the serum used for CRP detection
needed to be collected within 5 days before the tumor re-
section surgery. The biosensor detection system was ad-
justed regularly with a calibration curve acquired from the
four-parameter Logit log mode. All the reagents used in
CRP detection were derived from the WHO standards.
Statistical analysis
A receiver operating characteristic (ROC) curve analysis
was used to determine the preoperative serum CRP cut-
off value that was acceptable for patient case inclusion
in this study. The correlation between preoperative
serum CRP level and the clinicopathologic features of
the IHCC patients was evaluated by a χ2 test. Using uni-
variate analysis, survival curves were constructed using
the Kaplan-Meier method. The differences between
groups when considering survival were analyzed by the
log-rank test. The effect of preoperative serum CRP and
other clinicopathological variables on CSS and RFS were
evaluated with the Cox proportional hazards regression
model. For the variables with statistical significance in
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the univariate analysis, a further multivariate survival
analysis was performed with the Cox regression model.
The corresponding hazard ratio (HR) and 95 % confi-
dence interval (CI) were extracted from the Cox regres-
sion models. All statistical analyses were performed
using the SPSS statistical software package (SPSS Stand-
ard version 16.0, SPSS Inc.). A P < 0.05 in a two-sided
analysis was considered to be statistically significant.
Results
Patient characteristics
All patients underwent curative resection for IHCC with the
following intra-operative goals: complete tumor resection
with lymphoadenectomy and leaving the cut surface free of
tumor. Median tumor size was 5.5 cm (range from 0.5 to
15.0 cm). In this study, 140 IHCCs were located in right lobe
(74, 53 %), left lobe (47, 34 %), both right and left lobes (17,
12 %), and quadrate lobe (2, 1 %), respectively. Most patients
exhibited well-differentiated or moderately-differentiated tu-
mors (n = 91, 65 %). Vascular invasion was observed in 54
(39 %) patients. Intraepithelial ductal spread was detected in
88 of 140 (63 %) patients with IHCC. The elevated levels of
preoperative serum alanine aminotransferase (ALT) and as-
partate aminotransferase (AST) were observed in 53 (38 %)
and 43 (31 %) patients, respectively. Cancer recurrence was
observed in 87 patients, including 55 of intrahepatic relapse,
17 of multiple metastases, 12 of lymph node metastasis and
3 lung metastases. Patients received postoperative chemo-
therapy according to the status of lymph node metastasis
and multiple tumor nodules. The characteristics and patho-
logical features of IHCC patients are detailed in Table 1.
Preoperative serum CRP level cutoff selection
The mean pre-treatment plasma CRP level was 15.2 mg/L.
To develop an optimal serum CRP cutoff value for further
analysis, we subjected the serum CRP levels to an ROC
curve analysis with respect to the survival and recurrence
statuses (Fig. 1). The ROC curves showed the point on the
curve closest to (0.0, 1.0), which maximizes both the sensi-
tivity and specificity for the outcomes. Patients with cancer
with CRP levels above the obtained cutoff value have a
higher risk of tumor recurrence and cancer-related death
than cases with levels below the value. Based on the gath-
ered data, an optimal CRP level cutoff value of 1.8 mg/L
was determined to differentiate between the opposing pa-
tient prognoses (area under the curve: 0.659; 95 % CI:
0.570–0.749) (Fig. 1a) as well as between the tumor recur-
rence and no further incidence of tumors (area under the
curve: 0.659; 95 % CI: 0.566–0.752) (Fig. 1b).
Relationship between preoperative serum CRP level and
IHCC patient clinicopathological features
We separated patients into two groups according to low
CRP levels (≤1.8 mg/L) or high CRP levels (>1.8 mg/L)
according to the ROC curve analysis. We evaluated the
associations between preoperative serum CRP levels and
other clinicopathological factors gathered in the individ-
ual patient cases. An elevated serum CRP level was
significantly correlated with gender, advanced tumor
stage, elevated ALT, AST, carcinoembryonic antigen
(CEA), carbohydrate antigen 19-9 (CA19-9) levels and
intraepithelial ductal spread (P < 0.05). No significant asso-
ciations were found in between CRP level and age, tumor
location, hepatitis B virus infection, tumor size, tumor
grading, nodal metastasis, tumor multiplicity, vascular in-
vasion and chemotherapy administration (Table 1).
Relationship between preoperative serum CRP level and
IHCC patient survival
To investigate whether preoperative serum CRP level
and other clinicopathological factors are associated with
IHCC patient survival, we calculated univariate Cox
proportional models for the CSS and RFS. Univariate
analyses identified tumor size (≤5.5 vs >5.5 cm, P =
0.001), a high tumor stage (stage I/II vs III/IV, P = 0.007),
nodal metastasis (absent vs presence, P = 0.011), vascular
invasion (absent vs presence, P = 0.001), elevated CA19-
9 (≤35 vs >35 U/ml, P = 0.016), and a high serum CRP
level (≤1.8 vs >1.8 mg/L, P = 0.001) as poor prognostic
factors for CSS. For a poor prognosis of RFS, having a
larger tumor size (≤5.5 vs >5.5 cm, P = 0.001), a high
tumor stage (stage I/II vs III/IV, P = 0.025), nodal metas-
tasis (absent vs no presence, P = 0.016), vascular invasion
(absent vs presence, P = 0.003), postoperative chemotherapy
(chemotherapy vs on postoperative treatment, P < 0.001),
and a high serum CRP level (≤1.8 vs >1.8 mg/L, P < 0.001)
were identified as poor prognostic factors. Age, gender,
tumor location, grading, elevated ALT, ASTand CEA levels,
and tumor multiplicity were not significantly associated
with clinical outcomes for the set of patients (Table 2).
Among the 140 IHCC patients, death occurred in 11 of
42 (26 %) patients with a low serum CRP level and in 56
of 98 (57 %) patients with a high serum CRP level (P =
0.001). In the Kaplan–Meier survival analysis, there was
highly significant association between a high serum CRP
level and shortened patient survival time (P = 0.001,
Kaplan-Meier Method) (Fig. 2a). A stratified survival ana-
lysis was also performed to evaluate the serum CRP levels
in subsets of the IHCC patients that were at different clin-
ical stages. Our results demonstrated that a high serum
CRP level was a prognostic factor in IHCC patients with
stage I/II cancer (P = 0.006, Kaplan-Meier Method)
(Fig. 2c) but not stage III/IV cancer (P = 0.126, Kaplan-
Meier Method) (Fig. 2d).
Results in the RFS analysis were similar to that in CSS
analysis. Patients with high serum CRP level showed a sig-
nificant trend toward worse RFS compared to the RFS of
patients with low serum CRP levels (P < 0.001, Kaplan-
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Table 1 Correlation of preoperative serum C-reactive protein levels with patients’ clinico-pathological features in intra-hepatic
cholangiocarcinoma
Variable All cases Serum CRP mg/L P valuea
≤1.8 > 1.8
Age (years) 0.355
≤ 55b 75 21 (28.0 %) 54 (72.0 %)
> 55 71 21 (32.3 %) 44 (67.7 %)
Gender 0.018
Male 93 22 (23.7 %) 71 (76.3 %)
Female 47 20 (42.6 %) 27 (57.4 %)
Location 0.263
Right lobe 75 26 (34.7 %) 49 (65.3 %)
Left lobe 46 13 (28.3 %) 33 (71.7 %)
Both lobes or quadrate lobe 19 3 (15.8 %) 16 (84.2 %)
ALT < 0.001
Normal 87 37 (42.5 %) 50 (57.5 %)
Elevated 53 5 (9.4 %) 48 (90.6 %)
AST 0.002
Normal 97 37 (38.1 %) 60 (61.9 %)
Elevated 43 5 (11.6 %) 38 (88.4 %)
HbsAg 0.417
Positive 55 15 (27.3 %) 40 (72.7 %)
Negative 82 25 (30.5 %) 57 (69.5 %)
CEA (ng/ml) 0.047
≤ 5 101 35 (34.7 %) 66 (65.3 %)
> 5 38 7 (16.7 %) 31 (81.6 %)
CA19-9 (U/ml) 0.024
≤ 35 57 23 (40.4 %) 34 (59.6 %)
> 35 82 19 (23.2 %) 63 (76.8 %)
Tumor size (cm) 0.119
≤ 5.5c 71 25 (35.2 %) 46 (64.8 %)
> 5.5 69 17 (24.6 %) 52 (75.4 %)
Nodal metastasis 0.158
Yes 29 6 (20.7 %) 23 (79.3 %)
No 111 36 (32.4 %) 75 (67.6 %)
Tumor multiplicity 0.830
Single 108 32 (29.6 %) 76 (70.4 %)
Multiple 32 10 (31.2 %) 22 (68.8 %)
Intraepithelial ductal spread 0.039
Absent 52 21 (40.4 %) 31 (59.6 %)
Present 88 21 (23.9 %) 67 (76.1 %)
Vascular invasion 0.940
Absent 86 26 (30.2 %) 60 (69.8 %)
Present 54 16 (29.6 %) 38 (70.4 %)
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Meier Method) (Fig. 2b). Additionally, a stratified survival
analysis showed that a high serum CRP level was a pre-
dictor for RFS in both stage I/II cancers (P = 0.007,
Kaplan-Meier Method) (Fig. 2e) and stage III/IV cancers
(P = 0. 015, Kaplan-Meier Method) (Fig. 2f).
Independent prognostic value of preoperative serum CRP
levels in IHCC patients
To determine the independent prognostic value of the
serum CRP levels for CSS and RFS, we performed multi-
variate analyses using a Cox proportional hazard model.
The clinicopathologic variables, specifically tumor stage,
tumor size, nodal metastasis, vascular invasion, CA19-9
level, administration of postoperative chemotherapy, and
serum CRP levels, were tested in the multivariate ana-
lyses. The clinicopathological variables were found to be
of statistical significance in the univariate analyses. In
the multivariate analyses, we found that high serum CRP
level was a prognostic factor for poor CSS (P = 0.004)
and RFS (P < 0.001) of IHCC patients. Additionally, it
appeared that independent of tumor stage, nodal metas-
tasis and CA19-9 level were not prognostic factors for
poor CSS and RFS (Table 3). Despite this finding, tumor
size and vascular invasion were found to be independent
prognostic predictors for poor CSS and RFS, as well as
administration of postoperative chemotherapy for poor
RFS (P < 0.05) (Table 3).
Discussion
CRP is an acute-phase reactant, and plays a role in mi-
crobial infection, trauma, infarction, autoimmune dis-
eases, and malignant cancers [28]. Recently, high levels
Table 1 Correlation of preoperative serum C-reactive protein levels with patients’ clinico-pathological features in intra-hepatic
cholangiocarcinoma (Continued)
Grade 0.185
I 14 7 (50.0 %) 7 (50.0 %)
II 77 23 (29.9 %) 31 (70.1 %)
III 49 12 (24.5 %) 37 (75.5 %)
TNM 0.011
I-II 78 30 (38.5 %) 48 (61.5 %)
III- IV 62 12 (19.4 %) 50 (80.6 %)
Postoperative chemotherapy 0.078
Yes 47 10 (21.3 %) 37 (78.7 %)




CRP C-reactive protein, ALT alanine aminotransferase, AST aspartate aminotransferase, HbsAg hepatitis B surface antigen, CEA carcinoembryonic antigen, CA19-9
carbohydrate antigen 19-9, TNM tumor-node-metastasis
Fig. 1 Receiver operating characteristic curve analysis determination of cutoff score for preoperative serum C-reactive protein levels. The sensitivity
and specificity for each outcome were plotted: cancer-specific survival a, recurrence-free survival b
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Table 2 Univariate analyses of serum C-reactive protein (CRP) levels and clinicopathologic variables in 140 patients with intrahepatic
cholangiocarcinoma (Cox proportional-hazards regression)
Variables All cases Cancer-specific survival Recurrence-free survival
Hazard Ratio (95 % CI) P value Hazard Ratio (95 % CI) P value
Age (years)
≤ 55a 75 1 1
> 55 65 0.930 (0.572–1.513) 0.772 0.862 (0.562–1.321) 0.496
Gender
Male 93 1 1
Female 47 0.770 (0.455–1.301) 0.329 0.770 (0.488–1.214) 0.216
Location
Right lobe 75 1 1
Left lobe 46 1.329 (0.772–2.289) 0.304 1.224 (0.760–1.972) 0.407
Both lobes or quadrate lobe 19 1.192 (0.855–1.662) 0.300 1.217 (0.900–1.646) 0.202
ALT
Normal 87 1 1
Elevated 53 1.295 (0.794–2.110) 0.300 1.218 (0.791–1.874) 0.371
AST
Normal 97 1 1
Elevated 43 1.305 (0.783–2.175) 0.308 1.149 (0.729–1.812) 0.550
HbsAg
Positive 55 1.027 (0.629–1.675) 0.916 1.212 (0.785–1.871) 0.385
Negative 82 1 1
Tumor size (cm)
≤ 5.5b 71 1 1
> 5.5 69 2.315 (1.407–3.810) 0.001 2.072 (1.347–3.188) 0.001
Grade
I 14 1 1
II 77 0.490 (0.169–1.418) 0.188 0.363 (0.141–0.934) 0.036
III 49 0.910 (0.544–1.521) 0.719 0.794 (0.507–1.244) 0.314
Nodal metastasis
No 111 1 1
Yes 29 2.048 (1.169–3.589) 0. 011 1.847 (1.123–3.038) 0. 016
Tumor multiplicity
Single 108 1 1
Multiple 32 1.266 (0.729–2.198) 0.403 1.214 (0.742–1.985) 0.440
Intraepithelial ductal spread
Absent 52 0.821 (0.507–1.329) 0.422 0.897 (0.585–1.375) 0.618
Present 88 1 1
Vascular invasion
Absent 86 1 1
Present 54 2.298 (1.416–3.731) 0.001 1.901 (1.238–2.918) 0.003
TNM
I-II 78 1 1
III-IV 62 1.977 (1.203–3.249) 0.007 1.644 (1.065–2.536) 0.025
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of serum CRP have been associated with metastatic dis-
ease and a poor prognosis in various malignant cancers,
including perihilar cholangiocarcinoma. However, the
role of CRP status in IHCC, and its utility to clinicians, re-
mains unknown. In our study, we retrospectively assessed
IHCC patient cases in order to explore the prognostic
value of preoperative CRP. We sought to determine the
relative survival rates for IHCC patients who underwent
curative operations to remove cancerous tumors.
Our study demonstrated that preoperative serum CRP
levels were strongly associated with adverse CSS and
RFS in IHCC patients. Furthermore, the preoperative
serum CRP level appeared independent from tumor
characteristics and treatment allocation. Other groups
have reported similar results [23, 29–32], in which pre-
operative serum CRP level was significantly correlated
with other pathologic parameters found in solid cancers,
such as decreased survival times, increased loco-regional
recurrence rates, more severe post-operative complica-
tions, and a shorter relapse time after surgery. A more
recent study has found that C-reactive protein, at the
time of diagnosis, predicts poorer outcomes in hepato-
cellular carcinoma patients that are unable to have
tumor removal surgeries [33]. More importantly, high
CRP level was significantly correlated with poor survival
and found to be independently predictive of survival in
patients with perihilar cholangiocarcinoma as evidenced
by the in the univariate and multivariate analyses [27].
In summation, it appears the pre-operative CRP level
may be useful prognostic predictor in many cancer pa-
tients who have undergone a radical treatment to re-
move the cancer. Despite this finding, the prognostic
significance in IHCC patients that have not undergone
tumor removal surgery still needs further study.
In our study, subgroup analyses, with respect to the
TNM stage, supported the prognostic relevance of
serum CRP, except for the CSS rate in the subgroup of
TNM stage III–IV. This finding is inconsistent with the
previous studies, which imply a strengthened association
between serum CRP concentration and prognosis in
patients with advanced cancers, included colorectal can-
cer, gastric cancer, ovarian cancer, and renal cell cancer
[20, 34–37]. Notably, there is also a report [38] which
shows no significant prognostic value when considering
serum CRP level for predicting cancer recurrence rate in
stage II and III colorectal cancer. Taken together, differ-
ences in the geographic backgrounds, biological charac-
teristics of different tumors, selection of the CRP cutoff
valve, patient heterogeneity, small sample sizes, and dif-
ferent definitions of end points (disease-free, cancer spe-
cific survival, or overall survival) may contribute to these
discrepancies.
The underling mechanism regarding the elevated CRP
level indicating a potential poorer outcome for cancer
patients is unknown. There are three possible explana-
tions. First, this phenomenon could be explained by
causality, or that an elevated CRP level promotes tumor
progression. Second, this could be explained by reverse
causality, or that tumor progression increases the CRP
level. Lastly, there could be a confounding explanation.
A third factor, for example inflammation, could increase
both CRP level and tumor malignancy. Notably, there
are evidence [26] that the inflammatory field effect,
reflected by elevated CRP, may be directly involved in
tumor progression. This could explain the CRP level’s
prognostic significance in IHCC, which has a develop-
ment and progression that are closely related with in-
flammation [39, 40]. For example, IL-6, one of the main
Table 2 Univariate analyses of serum C-reactive protein (CRP) levels and clinicopathologic variables in 140 patients with intrahepatic
cholangiocarcinoma (Cox proportional-hazards regression) (Continued)
CEA (ng/ml)
≤ 5 101 1 1
> 5 38 1.276 (0.734–2.219) 0.388 1.317 (0.819–2.119) 0.255
CA19-9 (U/ml)
≤ 35 57 1 1
> 35 82 1.889 (1.125–3.169) 0.016 1.441 (0.930–2.234) 0.102
Postoperative chemotherapy
No 93 1 1
Yes 47 1.520 (0.925–2.498) 0.098 2.515 (1.619–3.908) <0.001
Serum CRP (mg/L)
≤ 1.8 42 1 1
> 1.8 98 2.965 (1.551–5.667) 0.001 2.751 <0.001
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inducers of CRP production, has been shown to be
associated with development and progression of cholan-
giocarcinoma and other cancers [28, 41]. Moreover, CRP
was shown to directly enhance tumor cell proliferation
under stressed conditions in a recent study on myeloma
[42]. Clearly, the causal mechanisms of CRP regarding
the progression of IHCC and other cancers need to be
clarified in further investigations.
The findings presented in this report may have impacts
for the design of future clinical trials. Most studies in ad-
vanced IHCC only stratify prognoses according to variables
like tumor staging and grading, presence or absence of vas-
cular invasion/extra-hepatic spread, and CEA or CA19-9
levels. The strong and independent prognostic significance
of serum CRP levels found in this study provides evidence
to collect serum CRP levels in future clinical trials for the
potential determination of an IHCC patient’s prognosis.
There are a few limitations in the design of this study.
CRP is known to be a non-specific marker of inflamma-
tion. It is possible that an undocumented super infection
could influence CRP concentrations in the serum. Fur-
thermore, as IHCC is mainly located within the liver, the
synthetic function of the hepatocytes may be affected.
This change in functioning may act as a confounding
factor that correlates directly with both the development
of IHCC and the serum concentration of CRP. More-
over, our study is limited by its retrospective nature and
a rather heterogeneous group of patients.
Fig. 2 Kaplan-Meier survival analysis of preoperative serum C-reactive protein (CRP) levels in patients with intrahepatic cholangiocarcinoma (IHCC)
(log-rank test). The preoperative serum CRP levels and the probability of cancer-specific survival (CSS, a) and recurrence-free survival (RFS) of IHCC
patients b The preoperative serum CRP levels and the probability of cancer-specific survival in IHCC patients at stage I-II c and stage III-IV d The
preoperative serum CRP levels and the probability of RFS in IHCC patients at stage I-II e and stage III-IV f
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Based on the results of our study, it is possible that a
higher preoperative CRP level in IHCC patients was asso-
ciated with a higher risk for recurrence and earlier death
because of the disease. Whether patients can be selected
for resection, or increase the chances of curative resection,
can only be evaluated in a controlled prospective clinical
trial. However, to the best of our knowledge, our study
represents the first one validates the prognostic value of
serum CRP levels in IHCC patient prognoses.
Conclusions
In conclusion, the preoperative CRP level was a strong
and independent predictor of a poor prognostic out-
come, as indicated by the univariate and multivariate
analyses. Adding the serum CRP into TNM stage factor
could improve the ability to discriminate between IHCC
patients’ outcomes. Our data seem to indicate that CRP
could function as an independent prognostic factor of
outcomes in IHCC. Additionally, the data support the
consideration of the preoperative CRP level for therapy
stratification. The causal role of CRP in tumor progres-
sion merits further investigation in preclinical studies.
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Table 3 Cox multivariate analyses of prognostic factors on patients’ survival
Variables Hazards ratio 95 % CI P value
Cancer-specific survivala
CA19-9, U/ml (≤35 v >35) 1.553 0.904–2.668 0.111
Tumor size, cm (≤5.5 v >5.5) 2.143 1.239–3.706 0.006
Nodal metastasis (absent v present) 1.390 0.703–2.749 0.343
Vascular invasion (absent v present) 1.954 1.181–3.233 0.009
TNM (I-II v III-IV) 0.884 0.459–1.702 0.711
Serum CRP, mg/L (≤1.8 v >1.8) 2.646 1.356–5.164 0.004
Recurrence- free survivalb
Postoperative chemotherapy (yes v no) 1.788 1.042–3.067 0.035
Tumor size, cm (≤5.5 v >5.5) 1.920 1.153–3.197 0.012
Nodal metastasis (absent v present) 1.277 0.689–2.367 0.437
Vascular invasion (absent v present) 1.733 1.107–2.715 0.016
TNM (I-II v III-IV) 0.663 0.369–1.191 0.169
Serum CRP, mg/L (≤1.8 v >1.8) 2.827 1.636–4.886 < 0.001
CI confidence interval, CA19-9 carbohydrate antigen 19-9, TNM tumor-node-metastasis, CRP C-reactive protein
aThe total number of patients and total number of events in this model were 140 and 67, respectively
bThe total number of patients and total number of events in this model were 140 and 87, respectively
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